Core Viewpoint - The stock of Xinmai Medical (688016) has experienced a decline, with a closing price of 107.63 yuan on October 13, 2025, down 2.67% from the previous day [1] Group 1: Stock Performance and Trading Data - On October 13, 2025, the stock had a turnover rate of 1.46%, with a trading volume of 18,000 hands and a total transaction amount of 193 million yuan [1] - The net inflow of main funds was 7.05 million yuan, accounting for 3.65% of the total transaction amount, while retail investors saw a net outflow of 5.28 million yuan, representing 2.73% of the total [1][2] - Over the past five days, the stock has shown a downward trend, with a closing price of 110.58 yuan on October 10, 2025, down 1.90%, and a net inflow of main funds of 7.95 million yuan [2] Group 2: Financing and Margin Trading Data - On October 13, 2025, the financing balance was 494 million yuan, with a net repayment of 38,300 yuan [3] - The stock had a margin trading balance of 496 million yuan, with a margin balance of 2.39 million yuan [3] - The stock's margin trading data indicates a consistent level of activity, with a total margin trading balance of 496 million yuan over the past five days [3] Group 3: Company Financial Performance - Xinmai Medical reported a main revenue of 714 million yuan for the first half of 2025, a year-on-year decrease of 9.24%, and a net profit of 315 million yuan, down 22.03% [5] - The company's gross profit margin stands at 69.19%, significantly higher than the industry average of 51.85% [5] - The company ranks 15th in net profit within the medical device industry, with a net profit margin of 43.48%, placing it second in the industry [5] Group 4: Industry Comparison and Ratings - Xinmai Medical has a total market value of 13.267 billion yuan, which is above the industry average of 11.888 billion yuan [5] - The company has received 12 ratings from institutions in the past 90 days, with 10 buy ratings and 2 hold ratings, and an average target price of 136.03 yuan [6]

Core Viewpoint - The company, Xinmai Medical, announced a cash dividend distribution and adjusted its share repurchase plan following the distribution, reflecting its ongoing commitment to returning value to shareholders [1][2][3]. Trading Information Summary - As of October 10, 2025, Xinmai Medical's stock closed at 110.58 yuan, down 1.9%, with a turnover rate of 1.27% and a trading volume of 15,600 shares, amounting to a total transaction value of 174 million yuan [1]. - On the same day, the net inflow of main funds was 7.95 million yuan, accounting for 4.56% of the total transaction value, while retail investors experienced a net outflow of 4.23 million yuan, representing 2.43% of the total transaction value [1][3]. Company Announcement Summary - Xinmai Medical announced a cash dividend of 1.3 yuan per share (tax included), with the record date set for October 16, 2025, and the ex-dividend date on October 17, 2025. The total cash dividend distribution amounts to approximately 157.19 million yuan (tax included) based on the adjusted share count [1][2]. - Following the dividend distribution, the upper limit for the second phase of the share repurchase plan was adjusted from 178.01 yuan per share to 176.73 yuan per share, effective from October 17, 2025. The total repurchase amount is set between 100 million yuan and 200 million yuan [2][4]. - As of September 30, 2025, the company had repurchased a total of 1,263,043 shares, representing 1.02% of the total share capital, with a cumulative repurchase amount of approximately 133 million yuan [3][4].

Core Points - The stock price of Xinmai Medical (688016) closed at 110.58 yuan on October 10, 2025, down 0.91% from the previous week [1] - The company has a total market capitalization of 13.63 billion yuan, ranking 24th in the medical device sector and 1415th among all A-shares [1] Company Announcements - Xinmai Medical announced a cash dividend of 1.3 yuan per share (tax included), with the record date on October 16, 2025, and the ex-dividend date on October 17, 2025. The total cash dividend distribution amounts to approximately 157.19 million yuan [2][5] - The company adjusted the maximum repurchase price from 178.01 yuan per share to 176.73 yuan per share, effective from October 17, 2025, due to the cash dividend distribution [2][5] - As of September 30, 2025, Xinmai Medical has repurchased a total of 1,263,043 shares, representing 1.02% of the total share capital, with a total repurchase amount of approximately 132.75 million yuan [3][5]

Group 1 - The company has approved a second phase of share repurchase plan, intending to buy back part of its issued A-shares using its own and/or self-raised funds, with a maximum repurchase price of RMB 180 per share and a total repurchase amount between RMB 100 million and RMB 200 million [2][9] - The repurchase period is set for 12 months from the board's approval date, and the shares will be used for employee stock ownership plans or equity incentives [2][9] - The maximum repurchase price has been adjusted to RMB 178.35 per share effective from November 8, 2024, and further adjusted to RMB 178.01 per share effective from June 6, 2025, due to the implementation of profit distribution [3][10] Group 2 - As of September 2025, the company has repurchased a total of 1,263,043 shares, accounting for 0.03% of the total share capital, with a total expenditure of approximately RMB 132.75 million [4] - The highest transaction price during the repurchase was RMB 120.00 per share, while the lowest was RMB 84.26 per share [4] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [7][15] Group 3 - The company has announced a cash dividend of RMB 1.3 per share for the 2025 semi-annual profit distribution, with the total number of shares participating in the distribution adjusted to 120,911,974 shares after excluding the repurchased shares [18][21] - The dividend distribution plan was approved during the annual general meeting held on April 18, 2025, and further reviewed by the board on August 26, 2025 [18][19] - The company will not distribute dividends to shares held in the repurchase special account, and the cash dividend will be distributed through the China Securities Depository and Clearing Corporation [19][24]

Core Viewpoint - The company has announced an adjustment to its share repurchase plan, lowering the maximum repurchase price from RMB 178.01 per share to RMB 176.73 per share, effective from October 17, 2025 [2] Summary by Relevant Sections - **Share Repurchase Plan** - The maximum repurchase price for the second phase of the share buyback has been adjusted to RMB 176.73 per share from the previous RMB 178.01 per share [2] - This adjustment will take effect on October 17, 2025 [2]

Core Viewpoint - On October 10, 2023, the company announced that it has repurchased a total of 34,300 A-shares through centralized bidding, representing 0.03% of the company's total share capital [2] Summary by Category Company Actions - The company has conducted a share buyback, acquiring 34,300 A-shares [2] - The repurchased shares account for 0.03% of the total share capital [2]

Group 1 - The core viewpoint of the article is that Xinmai Medical announced its profit distribution plan for the first half of 2025, which includes a cash dividend of 1.3 yuan per share (tax included) [2] - The record date for the dividend is set for October 16, 2025, while the ex-dividend date and the date of cash dividend distribution are both scheduled for October 17, 2025 [2]

Core Viewpoint - Shanghai MicroPort CardioFlow Medtech Co., Ltd. announced an adjustment to the upper limit of the share repurchase price following the implementation of the 2025 semi-annual profit distribution plan [1] Summary by Sections Price Adjustment Details - The upper limit of the repurchase price was adjusted from 178.01 CNY per share to 176.73 CNY per share, effective from October 17, 2025 [2][5] Share Repurchase Overview - On October 28, 2024, the company’s board approved a second phase of share repurchase through centralized bidding, with a repurchase price not exceeding 180 CNY per share and a total repurchase fund between 100 million CNY and 200 million CNY [3] Reason for Price Adjustment - The adjustment was necessary due to the cash dividend distribution of 1.3 CNY per share, which was approved in the board meetings and the annual shareholders' meeting, impacting the repurchase price [4] Repurchase Quantity Estimation - With the adjusted upper limit of 176.73 CNY per share, the estimated number of shares that could be repurchased ranges from approximately 565,834 shares (0.46% of total shares) to 1,131,669 shares (0.92% of total shares), depending on the total repurchase fund utilized [5] Other Conditions - All other aspects of the share repurchase plan remain unchanged, and the company will adhere to relevant regulations during the repurchase period [6]

证券代码：688016 证券简称：心脉医疗 公告编号：2025-040 上海微创心脉医疗科技（集团）股份有限公司 关于以集中竞价交易方式第二期回购股份的进展公告 2025 年 9 月，公司通过集中竞价交易方式已累计回购公司 A 股股份 34,300 股， 占公司总股本 123,262,117 股的比例为 0.03%，最高成交价为 108.98 元/股，最低成 交价为 103.82 元/股，成交总金额为人民币 3,672,982.00 元（不含印花税、交易佣 金等交易费用）。 截至 2025 年 9 月 30 日，公司通过上海证券交易所交易系统以集中竞价交易 方式（第二期）已累计回购公司股份 1,263,043 股，回购成交的最高价为 120.00 元 /股，最低价为 84.26 元/股，支付的资金总额为人民币 132,745,761.84 元（不含印 花税、交易佣金等交易费用）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/30 | | | | | | | --- ...

2024 年 7 月 23 日，公司召开第二届董事会第二十九次会议，审议通过了《关于以 集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上海证券交易 所系统以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股）股票，并在未 来适宜时机全部用于股权激励或员工持股计划。公司本次回购价格不超过人民币 130.00 元/股（含），回购资金总额不低于人民币 6,000.00 万元（含），不超过人民币 10,000.00 万元（含），回购股份的实施期限自董事会审议通过本次回购方案之日起 12 个月内。 2024 年 10 月 28 日，公司召开第三届董事会第二次会议，审议通过了《关于以集 中竞价交易方式第二期回购公司股份方案的议案》，同意公司以自有资金和/或自筹资 金通过上海证券交易所系统以集中竞价交易方式回购公司已发行的部分人民币普通股 （A 股）股票，并在未来适宜时机全部用于股权激励或员工持股计划。公司本次回购价 格不超过人民币 180 元/股（含），回购资金总额不低于人民币 10,000 万元（含），不 超过人民币 20,000 万元（含），回购股份的实施期限自董事会审议通过本次回购方案 之日 ...